Shionogi announced that it would acquire U.S.-based IntraBio for $2 billion to strengthen its development of drugs for neurological diseases. It will acquire all shares and bring in talent and expertise in the rare-disease field.
Shionogi agreed to acquire all shares of U.S. biopharmaceutical developer IntraBio for $2 billion (approximately ¥314 billion). The acquisition was announced on the 5th. The completion date was not stated in the article.
IntraBio was described as a company developing drugs for hereditary neurological diseases and other conditions. The acquisition is intended to bring in the company's talent and expertise in rare diseases.
Shionogi is reportedly seeking to accelerate development of its own new drug candidates through the acquisition of IntraBio.